Abstract:OBJECTIVE:To study the effects of RNA interference (RNAi)-mediated insulin-like growth factor I receptor (IGF-IR) gene silencing on human lung cancer cells. METHODS:Plasmids expressing IGF-IR shRNA1 and IGF-IR shRNA2 were constructed. Human non-small cell lung cancer cells of the line A549 were cultured and transfected with sequence-specific shRNA. RT-PCR was used to monitor the IGF-IR mRNA expression. Western blotting was used to detect the expression of IGF-IR, bcl-2 and caspase-3, associated with apoptosis, and IGF-IR signaling pathways-associated proteins, total and phospho-ERK1/2 and Akt. MTT assay and flow cytometry were used to examine the cell activity and cell cycle. Twelve nude mice were injected subcutaneously with A549 cells, 20 days later the mice were randomly divided into 3 groups to be injected into the tumor with IGF-IR, PBS, or blank plasmid respectively 4 times with the interval of 5 days. Five days after the 4th injection the mice were killed and the tumors were taken out. TUNNEL assay was used to detect the apoptotic cell in the tumor. RESULTS:RT-PCR showed that the IGF-IR mRNA expression level of the A549 cells transfected with IGF-IR shRNA1 was only 24% +/- 4% that of the A549 cells transfected with blank plasmid (P < 0.05); however, the IGF-IR mRNA expression level of the A549 cells transfected with IGF-IR shRNA2 was 78% +/- 5% that of the A549 cells transfected with blank plasmid (P > 0.05). The IGF-IR protein expression level of the A549 cells of the IGF-IR shRNA1 group was only 10.2% +/- 2.8% that of the A549 cells of the blank plasmid group (P < 0.05). Western blotting showed that the protein expression levels of bcl-2 and caspase-3p20 of the A549 cells of the IGF-IR shRNA1 group were 46% +/- 6% and 156% +/- 8% those of the negative controls (both P < 0.05); however, the protein expression levels of bcl-2 and caspase-3p20 of the A549 cells of the IGF-IR shRNA2 group were not different from those of the negative control cells. The Akt kinase and ERK phosphorylation levels of the A549 cells of the IGF-IR shRNA1 group were 10% and 36% +/- 3% those of the negative control cells respectively (both P < 0.05). Since 48h after the transfection the active cell number of the IGF-IR shRNA1 group was 64% +/- 7% that of the negative group (P < 0.05), and this decrease effect lasted to 72 h after (67% +/- 6% that of the negative cells, P < 0.05). 48 h after the transfection the percentage of cells at G(0)/G(1) phase of the IGF-IR shRNA1 group was 77.5%, significantly higher than that of the negative control group, and the percentages of the cells at S and G(2)/M phases of the IGF-IR shRNA1 group were 15.7% and 7.3% respectively, both significantly lower than those of the negative control group (23.0% and 29.9% respectively). Since the second injection the tumor size of the mice of IGF-IR shRNA group was 40% - 50% that of the PBS group (P < 0.05), and the tumor size of the mice of the PBS group was 90% that of the control group. TUNNEL assay showed that the number of apoptotic cells in the tumors of the IGF-IR shRNA1 group mice was 118 +/- 8/high power, significantly higher than that of the control group (70 +/- 9, P < 0.05). CONCLUSION:RNAi technique effectively inhibits the expression of IGF-IR, thus decreasing the NSCLC cell proliferation inducing apoptosis and inhibiting the tumor growth.

Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo

Treatment of Murine Breast Cancer Cells with Antisense RNA to the Type I Insulin-Like Growth Factor Receptor Decreases the Level of Plasminogen Activator Transcripts, Inhibits Cell Growth in Vitro, and Reduces Tumorigenesis in Vivo.

[Shrna-Mediated Insulin-Like Growth Factor I Receptor Gene Silencing Inhibits Cell Proliferation, Induces Cell Apoptosis, and Suppresses Tumor Growth in Non-Small Cell Lung Cancer: in Vitro and in Vivo Experiments].

Effect of antisense gene of type Ⅱ insulin-like growth factor receptor on malignant phenotype of human hepatoma cells in vitro

Suppression of Type 1 Insulin-Like Growth Factor Receptor Expression by Small Interfering Rna Inhibits A549 Human Lung Cancer Cell Invasion in Vitro and Metastasis in Xenograft Nude Mice

Down-Regulation of Igf-Ir Using Small, Interfering, Hairpin Rna (sirna) Inhibits Growth of Human Lung Cancer Cell Line A549 in Vitro and in Nude Mice

Abstract P2-26-13: Gene deletion of insulin receptor in MCF-7L breast cancer cells by CRISPR gene editing

Effect on Growth of Human Hepatoma Cells by Antisense Gene of Type II Insulin-Like Growth Factor Receptor Transfection

Shrna-Mediated IGF-1R Silencing Inhibits Proliferation and Migration of Breast Cancer Cell MDA-MB-231 in Vitro

Growth Inhibition of Insulin-Like Growth Factor I Receptor Monoclonal Antibody to Human Colorectal Cancer Cells

Down-regulation of IGF-1R Expression Inhibits Growth and Enhances Chemosensitivity of Endometrial Carcinoma in Vitro

Silencing of the type 1 insulin-like growth factor receptor increases the sensitivity to apoptosis and inhibits invasion in human lung adenocarcinoma A549 cells

The inhibited effect of RNA interference technology silencing IGF-1R on endometrial carcinoma proliferation and tumorigenesis in nude mice

Targeting the IGF1R Pathway in Breast Cancer Using Antisense lncRNA-Mediated Promoter cis Competition

Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells

Biological Behaviors and Chemosensitivity of NSCLC A549 Cells after IGF-I R Gene Silencing by Targeting RNAi in Vitro

Effects of Insulin-Like Growth Factor 1 Receptor and Its Inhibitor AG1024 on the Progress of Lung Cancer

Inhibition Of Insulin-Like Growth Factor-I Receptor (Igf-Ir) Signaling And Tumor Cell Growth By A Fully Human Neutralizing Anti-Igf-Ir Antibody

Enhancement of immunogenicity of tumor cells by cotransfection with genes encoding antisense insulin-like growth factor-1 and B7.1 molecules

Silencing insulin-like growth factor-1 receptor expression inhibits gastric cancer cell proliferation and invasion.

Prognostic significance of IGF-1R expression in patients treated with breast-conserving surgery and radiation therapy